重组人血管内皮抑制素联合化疗治疗晚期恶性肿瘤  

Recombinant Human Endostatin Combined with Chemotherapy in the Treatment of Advanced Malignant Tumors

作　　者：李绮云[1] 陈永锋[1] 林王美[1] 

机构地区：[1]广东省农垦中心医院肿瘤内科,广东湛江524002

出　　处：《肿瘤基础与临床》2011年第4期305-306,共2页journal of basic and clinical oncology

摘　　要：目的观察重组人血管内皮抑制素(恩度)联合化疗治疗晚期恶性肿瘤的疗效和毒副反应。方法 25例经病理组织学或细胞学检查确诊的晚期恶性肿瘤患者,均采用恩度联合化疗方案,恩度15 mg静脉滴注3～4 h,d1～14连续给药,同时给予以往未使用过的或既往治疗无交叉耐药的化疗药物,每3周重复。2个周期后评价疗效和毒副反应。结果 25例中23例可评价疗效,CR 0例,PR6例,SD12例,PD5例,有效率及疾病控制率分别为26.1%(6/23)、78.3%(18/23);未出现严重的毒副反应。结论恩度联合化疗治疗晚期恶性肿瘤具有协同作用,可以改善患者的生活质量,毒副反应可耐受。Objective To investigate the efficacy and toxicities of recombinant human endostatin（endostar） combined with chemotherapy in the treatment of the advanced malignant tumors.Methods Twenty-five patients with advanced malignant tumor confirmed by histopathology or cytopathology were administrated with endostar 15 mg（days 1-14） by vein infusion of 3-4 hours and routine chemotherapy every 3 weeks.The efficacy and toxicities were observed after 2 cycles.Results Twenty-five patients were entered,23 patients were evaluable.CR was observed in 0 patient,PR in 6 patients,SD in 12 patients and PD in 5 patients.The response rate was 26.1%（6/23）,the disease control rate was 78.3%（18/23）.No serious toxicites were observed.Conclusion The qualtity of life of patients with advanced malignant tumor may be improved by endostar combined with chemotherapy.The toxicities can be tolerated.

关 键 词：重组人血管内皮抑制素 晚期恶性肿瘤 化疗 

分 类 号：R730.58[医药卫生—肿瘤] R730.53[医药卫生—临床医学]